Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cash from Investing Activities (2020 - 2025)

Insight Molecular Diagnostics' Cash from Investing Activities history spans 6 years, with the latest figure at -$1.0 million for Q3 2025.

  • For Q3 2025, Cash from Investing Activities fell 1106.9% year-over-year to -$1.0 million; the TTM value through Sep 2025 reached -$1.9 million, down 862.81%, while the annual FY2024 figure was -$512000.0, 45.06% up from the prior year.
  • Cash from Investing Activities for Q3 2025 was -$1.0 million at Insight Molecular Diagnostics, down from -$349000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $214000.0 in Q3 2023 and bottomed at -$8.3 million in Q1 2021.
  • The 5-year median for Cash from Investing Activities is -$394000.0 (2021), against an average of -$1.1 million.
  • The largest annual shift saw Cash from Investing Activities surged 124.91% in 2023 before it tumbled 1179.17% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at -$401000.0 in 2021, then plummeted by 100.0% to -$802000.0 in 2022, then surged by 112.84% to $103000.0 in 2023, then tumbled by 303.88% to -$210000.0 in 2024, then plummeted by 400.0% to -$1.0 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Cash from Investing Activities are -$1.0 million (Q3 2025), -$349000.0 (Q2 2025), and -$307000.0 (Q1 2025).